x
- Home
- Diabetes Models
- In Vivo Models of Diabetes Mellitus
- In Vitro Models of Diabetes Mellitus
- Diabetes Drug R&D Services
- Therapeutic Areas
- Virtual Booth
- Company
Ace Therapeutics has established a robust in vitro efficacy assessment platform for antidiabetic drugs, offering comprehensive solutions to our global clients to facilitate the advancement of their antidiabetic drug development programs. We offer a wide range of in vitro models and customized in vitro efficacy assessment tests designed to fully support our clients' different testing needs. Our strong portfolio of services enables our clients to conduct in vitro tests in a more efficient and cost-effective manner, while facilitating the screening of high-quality antidiabetic drugs with good efficacy.
In vitro efficacy assessment is an essential part of the preclinical evaluation framework for antidiabetic drugs. Specialized in vitro efficacy assessment provides important insights into the mechanism of action of antidiabetic drugs and provides the basis for INDs for drug submissions. Ace Therapeutics' in vitro efficacy assessment services focus on the specific mechanisms by which antidiabetic substances work, typically involving cultured cell lines and various biochemical assays.
We have established multiple in vitro models and developed a range of in vitro efficacy assessment tests for different targets. These tests can provide reliable data for the overall efficacy evaluation of antidiabetic drugs, which will facilitate early drug development.
With years of research experience, Ace Therapeutics is able to provide comprehensive in vitro efficacy assessment services. We employ a range of different assays to comprehensively test and analyze the efficacy and activity of antidiabetic drug candidates, in accordance with our clients' requirements.
| In Vitro Efficacy Assays | Introduction |
|---|---|
| Enzyme activity inhibition assay | We assess the inhibitory effects of antidiabetic drugs on different enzyme activities, including α-amylase, α-glucosidase, pancreatic lipase, dipeptidyl peptidase IV (DPP-IV), collagenase, and CYP3A4. |
| Glucose uptake assay | This assay is primarily used to evaluate the antidiabetic activity of compounds by assessing their ability to enhance glucose uptake. We offer various types of glucose uptake assays, including the use of radiolabeled or non-radiolabeled glucose analogues. |
| Insulin secretion assay | We utilize ELISA-based and luciferase-based assays to quantify the effects of antidiabetic drugs on insulin secretion. |
| Reporter gene assay | To examine the effects of antidiabetic drugs on the expression of diabetic target genes such as peroxisome proliferator-activated receptor gamma (PPARγ), potassium inward rectifier channel subfamily J member 11 (KCNJ11) and ATP-binding cassette transporter subfamily C member 8 (ABCC8). |
| Calcium measurement assay | Direct or indirect release of intracellular Ca2+ may lead to insulin secretion. We assess the activity of antidiabetic drugs by directly measuring intracellular Ca2+ content. |
| ATP measurements assay | Intracellular ATP levels are measured to evaluate the activity of antidiabetic drugs. |
| cAMP assay | As a critical regulator of insulin secretion, cAMP levels are measured to indirectly evaluate the effects of antidiabetic drugs on this process. |
| PPARγ and GLUT-4 assay | We assess the effects of antidiabetic drugs on glucose uptake by measuring their effects on PPARγ and GLUT4 expression. |
| PTP1B assay | PTP1B analysis is used to assess the dephosphorylation of insulin receptors and determine the effects of antidiabetic drugs on glucose uptake. |
Ace Therapeutics is committed to leveraging our efficient in vitro assessment process to aid your antidiabetic drug development program. Please contact us for more details. We will work with you to design a scientifically sound in vitro efficacy assessment program to meet your drug development needs.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
